AbbVie Q3 revenue beats expectations on neuroscience portfolio expansion; raises outlook
ABBV•AbbVie’s third-quarter revenue rose 10.3% year over year to $17.40 billion, beating expectations, while adjusted EPS of $3.82 also topped estimates. The company raised its 2026 adjusted diluted EPS guidance to $13.95-$13.99.
1. Quarterly results
AbbVie reported third-quarter revenue of $17.40 billion, up 10.3% year over year and above the $17.31 billion analyst consensus. Adjusted EPS was $3.82, beating the $3.75 consensus; reported EPS was $2.37.
2. Portfolio performance
Immunology revenue rose 16.3%, driven by Skyrizi and Rinvoq. Neuroscience revenue increased 19.4%, led by Vraylar, Botox Therapeutic, Ubrelvy and Qulipta, while Humira revenue fell 31.2%.
3. Outlook and pipeline
AbbVie raised its 2026 adjusted diluted EPS guidance to $13.95-$13.99 and completed its acquisition of Apogee Therapeutics. The company expects additional lutikizumab data in hidradenitis suppurativa to support regulatory submissions in the second half of 2027.
